Skip to main content

Table 1 Patient baseline characteristics

From: A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

Characteristic Pomalidomide plus dexamethasone (N = 36)
Age
 Median (range), years 64.5 (43–78)
 >65 years, n (%) 17 (47.2)
 >75 years, n (%) 4 (11.1)
Sex, n (%)
 Male 16 (44.4)
 Female 20 (55.6)
Time from first diagnosis, median (range), years 4.7 (0.6–21.1)
ECOG performance status, n (%)
 0–1 33 (91.7)
 2 3 (8.3)
Durie–Salmon stage, n (%)
 I 7 (19.4)
 II 16 (44.4)
 III 13 (36.1)
β2-microglobulin level, n (%)
 <3.5 mg/L 24 (66.7)
 3.5–<5.5 mg/L 10 (27.8)
 ≥5.5 mg/L 2 (5.6)
Bone lesions, n (%) 22 (61.1)
Extramedullary plasmacytoma, n (%) 5 (13.9)
Creatinine clearance, n (%)
 <30 mL/min 0
 30–<45 mL/min 0
 45–<60 mL/min 8 (22.2)
 60–<80 mL/min 13 (36.1)
 ≥80 mL/min 15 (41.7)
Prior antimyeloma therapies, median (range) 6.5 (2–15)
Prior stem cell transplant, n (%) 19 (52.8)
Prior therapies, n (%)
 Lenalidomide 36 (100.0)
 Bortezomib 36 (100.0)
 Thalidomide 12 (33.3)
 Dexamethasone 35 (97.2)
 Melphalan 31 (86.1)
Last prior therapy, n (%)
 Lenalidomide 21 (58.3)
 Bortezomib 15 (41.7)
Refractory to prior therapies, n (%)
 Lenalidomide 35 (97.2)
 Bortezomib 21 (58.3)
 Both lenalidomide and bortezomib 21 (58.3)
  1. ECOG Eastern Cooperative Oncology Group